PHARM Pharming Group NV

Pharming Group to participate in March investor conference

Pharming Group to participate in March investor conference

Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March:

  • 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025

    Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.

For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at or your Roth representative.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit and find us on .

For further public information, contact:

Pharming Group, Leiden, the Netherlands

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E:

FTI Consulting, London, United Kingdom

Simon Conway/Alex Shaw/Amy Byrne

T: 0

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands

Leon Melens

T: 27

E:

Attachment



EN
28/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharming Group NV

 PRESS RELEASE

Pharming Group reports first quarter 2025 financial results and provid...

Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adju...

 PRESS RELEASE

Pharming Group announces the 2025 Annual General Meeting of Shareholde...

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decide...

 PRESS RELEASE

Pharming Group announces upcoming presentations at the 2025 Annual Mee...

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3K...

 PRESS RELEASE

Pharming receives positive recommendation from NICE for Joenja®▼(lenio...

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive f...

 PRESS RELEASE

Pharming Group announces the filing of its 2024 Annual Report and Form...

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found und...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch